7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series (Q44781825)

6 December 2017

title

7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series (English)

1 reference

pneumococcal conjugate vaccine

6 December 2017

main subject

1 reference

based on heuristic

inferred from title

respiratory tract infection

1 reference

1 reference

6 December 2017

Derek Weycker

1 reference

6 December 2017

Jerome O Klein

1 reference

6 December 2017

David Strutton

1 reference

6 December 2017

Vincent Ciuryla

1 reference

6 December 2017

Gerry Oster

1 reference

6 December 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

1575-1582

1 reference

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Progress in the prevention of pneumococcal infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Experience with pneumococcal conjugate vaccine in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

A role for Streptococcus pneumoniae in virus-associated pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.053

10.1016/J.VACCINE.2009.11.053

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference